Blandt de forsøgspersoner med en abnorm Pap- test ved dag 1, som var naive over for de relevante vaccine- HPV- typer ved dag 1, forblev vaccinens effekt høj.
Among subjects with an abnormal Pap test at Day 1 who were naïve to the relevant vaccine HPV types at Day 1, efficacy of the vaccine remained high.